Boston Scientific Outlines Near‑Term Priorities and Clinical Progress at TD Cowen Webcast

Executive Q&A to Map Near‑Term Priorities at TD Cowen

Boston Scientific is presenting senior leadership at TD Cowen’s 46th Annual Health Care Conference to outline near‑term strategic priorities and recent clinical progress. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, are scheduled for a roughly 30‑minute question‑and‑answer session with the host analyst on March 3, 2026, at about 9:10 a.m. ET. The company frames the session as an opportunity to discuss how its portfolio of devices and therapies across cardiovascular, respiratory, digestive, oncological, neurological and urological disease areas is evolving to meet clinical needs and reduce healthcare costs.

The appearance places clinical evidence and commercialization at the center of the company’s messaging. Boston Scientific signals it will use the forum to review recent clinical data, product launches and the execution of its broader strategy to drive adoption across hospital and outpatient settings. Company executives typically face direct questions on regulatory timelines, trial readouts and how new technologies integrate with existing treatment pathways; this Q&A is positioned to provide a concise update on those operational priorities rather than detailed financial guidance.

Boston Scientific also intends the presentation to reinforce its innovation narrative after more than 45 years as a medical‑technology company. The format — a live webcast followed by a replay available about an hour after the session ends — enables clinicians, partners and health‑care purchasers to hear management’s account of near‑term milestones and commercialization plans. The session is likely to touch on cross‑portfolio synergies, efforts to expand minimally invasive treatment options and initiatives aimed at driving better outcomes while containing costs.

Quarterly results underpin commercial narrative

In related disclosures, Boston Scientific reports fourth‑quarter 2025 net sales of $5.286 billion, a 15.9% reported increase year‑over‑year, which the company says underscores commercial momentum ahead of the March 3 presentation. Management is expected to reference that momentum when discussing adoption trends and market access.

Webcast logistics and contact points

The live webcast and replay are accessible at https://investors.bostonscientific.com. Media and investor contacts listed in the release include Chanel Hastings, Media Relations, and Lauren Tengler, Investor Relations. Boston Scientific directs stakeholders to its corporate website and LinkedIn for further materials and future announcements.